Project Grant R43AR063129

This Project Grant award of $147,400.00, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the mechanisms by which antigen non-related CD4+ T cells contribute to the pathogenesis of skin fibrosis in systemic sclerosis (scleroderma) and sclerodermoid graft-versus-host disease. The project, conducted by Yale University, will use mouse models to...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) provides $173,719.00 to Boston University Medical Campus to conduct research on using Spatial Frequency Domain Imaging (SFDI) as an objective method to quantify and monitor skin changes in patients with Systemic Sclerosis (SSc), a severe autoimmune connective tissue disease. The research aims to prospectively evaluate SFDI's...

The University of California, San Francisco will conduct research on NR4A family proteins as markers and mediators of B cell tolerance in systemic lupus erythematosus (SLE) under a three-year, $738,631 Project Grant from the Department of the Army Medical Command. The grant is part of the Military Medical Research and Development program administered by the Department of Defense and aims to transform military and public health through innovative medical research solutions for battlefield...

The University of Massachusetts Medical School was awarded a $494,929 Project Grant from the National Institute of Allergy and Infectious Diseases to study the role of Toll-like receptors, type II interferon and type III interferon in a murine model of autoinflammation. The grant will support research exploring the effector mechanisms responsible for inducing and regulating cutaneous lupus using genetically modified mice with discriminating mutations. Specifically, the researchers will use...

The National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University School of Medicine $409,311.92 under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) from April 5, 2021 to January 25, 2022. The project grant funding supports research into the role of T follicular helper (TFH) cells in the pathogenesis of dermatomyositis, a severe inflammatory myopathy. Specifically, the award will fund studies to...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $715,957.00 to Northwestern University to conduct research on the mechanisms by which type I interferon cytokines support the production and expansion of T peripheral helper (Tph) cells in systemic lupus erythematosus (SLE) patients. The research aims to elucidate the molecular pathways...

Federal Project Grant Award Summary The University of Massachusetts Medical School received a $249,000 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective July 1, 2025, through June 30, 2028. The award funds the development of a programmable small interfering RNA (siRNA)-based therapeutic platform for gene silencing in skin diseases. The research...

Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $504,442 Project Grant (CFDA 93.846: Arthritis, Musculoskeletal and Skin Diseases Research) to the University of Pittsburgh, effective September 2, 2025, through August 31, 2030. This award funds research to characterize molecular endotypes in pediatric scleroderma—encompassing both juvenile systemic sclerosis (JSSC) and juvenile localized scleroderma (JLS)—through...

This $375,100 federal Project Grant award was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant funds a study to investigate the interplay between nucleic-acid-dependent phase separation and immune responses against cyclic GMP-AMP synthase (cGAS) in systemic lupus erythematosus (SLE). The research aims to determine how changes in the biophysical...

Federal Grant Award Summary: Bispecific Biologic for Rheumatoid Arthritis Therapy Knoubis Bio Inc. received a $312,323 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop a novel bispecific biologic therapeutic for rheumatoid arthritis (RA). The award was obligated on July 15, 2025, with a project completion date of June 30, 2026. Under this...